Testosterone Replacement Therapy for Secondary Hypogonadism

Diagnosis and Assessment

The European Association of Urology recommends that secondary hypogonadism must be confirmed through both persistent specific symptoms and laboratory confirmation of decreased morning total testosterone levels 1, 4
Assessment should include evaluation for pituitary disorders, surgical history, comorbidities, and medications affecting the hypothalamic-pituitary-gonadal axis, as recommended by the European Urology guidelines 1
Morning total testosterone concentration should be drawn between 8-10 AM, according to the Gastroenterology guidelines 5, 6
Free testosterone level by equilibrium dialysis and sex hormone-binding globulin level should be measured, especially in obese patients, as recommended by the Gastroenterology guidelines 5, 6
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) measurements should be used to confirm secondary (pituitary-hypothalamic) hypogonadism, according to the Gastroenterology guidelines 5, 6

The European Urology guidelines recommend TRT as the first-line treatment for symptomatic secondary hypogonadism when fertility is not an immediate concern 1, 3
TRT is strongly recommended as first-line treatment for hypogonadal patients with mild erectile dysfunction, according to the European Urology guidelines 1, 2
For more severe erectile dysfunction, the European Urology guidelines suggest considering a combination of TRT with phosphodiesterase type 5 inhibitors 1, 2
The European Urology guidelines recommend that TRT is contraindicated in men seeking fertility as it suppresses spermatogenesis 1, 3, 7

The European Urology guidelines recommend that multiple testosterone formulations are available, with selection based on clinical characteristics, availability, and patient preferences 1, 3
Transdermal preparations (gel, patch) provide relatively stable testosterone levels but may have variable absorption and potential for transfer to others, according to the Gastroenterology guidelines 5, 6
Intramuscular injections offer less frequent administration but can cause fluctuating testosterone levels, as recommended by the Gastroenterology guidelines 5, 6
Implantable pellets provide long-term treatment but require a procedure for implantation, according to the Gastroenterology guidelines 5, 6

The European Urology guidelines recommend that functional hypogonadism commonly correlates with obesity and metabolic disorders 1, 3
Weight loss through diet and physical activity can reverse obesity-associated secondary hypogonadism, according to the European Urology guidelines 1, 3
Lifestyle modifications should be recommended but may yield modest testosterone increases, as recommended by the European Urology guidelines 1, 3
The European Urology guidelines suggest considering combining lifestyle changes with TRT for better outcomes in symptomatic patients 1, 3

Active or treated male breast cancer is an absolute contraindication for TRT, according to the European Urology guidelines 1, 3, 7
Desire for fertility in the near future is a contraindication for TRT, as recommended by the European Urology guidelines 1, 3, 7
Prostate cancer requires cautious use of TRT, especially in advanced disease, according to the European Urology guidelines 3, 7
Severe lower urinary tract symptoms require cautious use of TRT, as recommended by the European Urology guidelines 1, 3
Cardiovascular disease requires individual risk assessment, according to the Mayo Clinic Proceedings guidelines 8, 9

Follow-up monitoring should include clinical response assessment at 3 months, as recommended by the European Urology guidelines 3, 7
Testosterone levels should be measured 2-3 months after treatment initiation, according to the Gastroenterology guidelines 5, 6
Hematocrit should be monitored and phlebotomy considered if >54%, as recommended by the European Urology guidelines 3, 7
PSA monitoring is recommended, according to the European Urology guidelines 3, 7

The European Urology guidelines recommend against using TRT in eugonadal men 1, 2
TRT should not be used to reduce weight or enhance cardiometabolic status as primary goal, as recommended by the European Urology guidelines 1, 2
TRT should not be used to improve cognition, vitality, or physical strength in aging men without documented hypogonadism, according to the European Urology guidelines 1, 2
Testosterone levels should not be tested during acute illness as they may be falsely low, as recommended by the European Urology guidelines 1, 4
Fertility concerns should not be overlooked when initiating TRT in men of reproductive age, according to the European Urology guidelines 1, 3, 7